Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,589,090
  • Shares Outstanding, K 127,227
  • Annual Sales, $ 829,250 K
  • Annual Income, $ 281,590 K
  • EBIT $ 548 M
  • EBITDA $ 634 M
  • 60-Month Beta 1.29
  • Price/Sales 9.30
  • Price/Cash Flow 19.08
  • Price/Book 17.04

Options Overview Details

View History
  • Implied Volatility 32.65% ( +0.99%)
  • Historical Volatility 55.69%
  • IV Percentile 12%
  • IV Rank 39.99%
  • IV High 51.68% on 02/16/24
  • IV Low 19.97% on 06/04/24
  • Put/Call Vol Ratio 0.20
  • Today's Volume 97
  • Volume Avg (30-Day) 559
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 13,403
  • Open Int (30-Day) 11,488

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.13
  • Number of Estimates 6
  • High Estimate 1.29
  • Low Estimate 1.05
  • Prior Year 0.75
  • Growth Rate Est. (year over year) +50.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.84 +23.91%
on 10/25/24
61.49 -1.58%
on 11/06/24
+6.39 (+11.80%)
since 10/08/24
3-Month
48.84 +23.91%
on 10/25/24
65.53 -7.65%
on 08/29/24
+6.06 (+11.13%)
since 08/08/24
52-Week
33.15 +82.56%
on 02/05/24
65.53 -7.65%
on 08/29/24
+23.77 (+64.68%)
since 11/08/23

Most Recent Stories

More News
Halozyme Therapeutics: Q3 Earnings Snapshot

Halozyme Therapeutics: Q3 Earnings Snapshot

HALO : 60.87 (+2.05%)
Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options

Investors in Halozyme Therapeutics, Inc. HALO need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2024 $17.5 Call had some of the highest implied...

HALO : 60.87 (+2.05%)
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies

/CNW/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase...

ONCY : 1.0300 (-3.74%)
ACLX : 105.72 (+6.62%)
ONC.TO : 1.43 (-4.67%)
GTHX : 7.15 (unch)
HALO : 60.87 (+2.05%)
SNY : 51.47 (-0.50%)
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates

/CNW/ -- USA News Group – Pancreatic cancer is among the deadliest cancers, prompting researchers to focus on early detection to improve survival rates. Johns...

ONCY : 1.0300 (-3.74%)
HALO : 60.87 (+2.05%)
CADL : 4.87 (-4.32%)
MRUS : 54.51 (+0.02%)
RHHBY : 37.4500 (-1.89%)
ONC.TO : 1.43 (-4.67%)
Biotech Innovations Poised to Transform Pancreatic Cancer Treatment and Patient Outcomes

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – Pancreatic cancer is among the...

ONCY : 1.0300 (-3.74%)
ONC.TO : 1.43 (-4.67%)
RHHBY : 37.4500 (-1.89%)
HALO : 60.87 (+2.05%)
CADL : 4.87 (-4.32%)
MRUS : 54.51 (+0.02%)
Halozyme Therapeutics: Q2 Earnings Snapshot

Halozyme Therapeutics: Q2 Earnings Snapshot

HALO : 60.87 (+2.05%)
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/CNW/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding...

ONCY : 1.0300 (-3.74%)
CADL : 4.87 (-4.32%)
AZN : 64.61 (-0.12%)
HALO : 60.87 (+2.05%)
JANX : 54.88 (+1.24%)
ONC.TO : 1.43 (-4.67%)
Rising Cancer Rates Drive Biotech Advancements Despite Political Hurdles

USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden’s “Cancer...

ONCY : 1.0300 (-3.74%)
ONC.TO : 1.43 (-4.67%)
CADL : 4.87 (-4.32%)
AZN : 64.61 (-0.12%)
HALO : 60.87 (+2.05%)
JANX : 54.88 (+1.24%)
Halozyme Therapeutics: Q1 Earnings Snapshot

Halozyme Therapeutics: Q1 Earnings Snapshot

HALO : 60.87 (+2.05%)
Halozyme Therapeutics: Q4 Earnings Snapshot

Halozyme Therapeutics: Q4 Earnings Snapshot

HALO : 60.87 (+2.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company...

See More

Key Turning Points

3rd Resistance Point 63.00
2nd Resistance Point 61.98
1st Resistance Point 60.81
Last Price 60.87
1st Support Level 58.62
2nd Support Level 57.60
3rd Support Level 56.43

See More

52-Week High 65.53
Last Price 60.87
Fibonacci 61.8% 53.16
Fibonacci 50% 49.34
Fibonacci 38.2% 45.52
52-Week Low 33.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar